The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma : Episode 3
Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma
This video episode explores data supporting ide-cel in the second-line setting for multiple myeloma, highlighting key findings from the KarMMa and KarMMa-3 trials, comparisons to other options, and clinical experiences regarding efficacy, quality of life benefits, and implementation challenges.
Video content above is prompted by the following:
- Let's review the data supporting ide-cel in this scenario:
- What key findings from the KarMMa and KarMMa-3 trials inform your decision?
- How do these results compare to other second-line options for multiple myeloma?
- Discuss your experience using ide-cel in the second-line setting:
- What benefits have you observed in terms of efficacy and quality of life?
- What challenges have you encountered in implementing this treatment?
Recent Videos
Related Content
